Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 18/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 18/20 | 0.64 |
| ▸ | PDE4A | P27815 | 3/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.61 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.56 |
| ▸ | GALR3 | O60755 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8342501 | 1.00 | PDE3B (0.64) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10353457 | 0.93 | PDE3B (0.71) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL22317993 | 0.87 | PDE3B (0.64) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9687674 | 0.87 | PDE3B (0.64) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL11633346 | 0.87 | PDE3B (0.64) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL16157007 | 0.85 | PDE3B (0.71) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL16157017 | 0.85 | PDE3B (0.62) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL11571863 | 0.85 | PDE3B (0.71) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL11397791 | 0.85 | PDE3B (0.62) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL7338020 | 0.85 | PDE3B (0.66) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000158-B2 | Process for preparing levosimendan and intermediates for use in the process | CIPLA LIMITED (IN) | 2015-04-07 | — | — | US | disclosed |
| US-20120165524-A1 | Process for Preparing Levosimendan and Intermediates for Use in the Process | CIPLA LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165524-A1 | Process for Preparing Levosimendan and Intermediates for Use in the Process | CYP3A5, HTR5A, CYP2D6 | PDE3B 375/4885PDE3A 220/4885PDE4A 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.